160 related articles for article (PubMed ID: 31701575)
1. Nivolumab for adjuvant treatment of desmoplastic malignant melanoma: A case report.
Shibata T; Iwashita N; Takama H; Yanagishita T; Takeo T; Oshima Y; Watanabe D; Tsuzuki T
J Dermatol; 2020 Jan; 47(1):e6-e7. PubMed ID: 31701575
[No Abstract] [Full Text] [Related]
2. Dermoscopic changes in malignant melanoma after successful treatment with nivolumab: A case report.
Yamamura K; Otsuka A; Kaku Y; Seidel JA; Nomura M; Nagai H; Matsumoto S; Kabashima K
J Dermatol; 2017 May; 44(5):547-548. PubMed ID: 27461159
[No Abstract] [Full Text] [Related]
3. Induction of Immune Reaction in Benign Melanocytic Nevi Without Halo During Nivolumab Therapy in a Patient With Melanoma.
Nakamura Y; Fujino T; Kagamu H; Matsuya T; Teramoto Y; Asami Y; Yamamoto A
JAMA Dermatol; 2017 Aug; 153(8):832-834. PubMed ID: 28492864
[No Abstract] [Full Text] [Related]
4. Should adjuvant nivolumab be used in surgically resected Merkel cell carcinoma patients?
Saiag P; Blom A
Lancet; 2023 Sep; 402(10404):751-753. PubMed ID: 37451294
[No Abstract] [Full Text] [Related]
5. PIVOT-12: a phase III study of adjuvant bempegaldesleukin plus nivolumab in resected stage III/IV melanoma at high risk for recurrence.
Eggermont AM; Ascierto PA; Khushalani NI; Schadendorf D; Boland G; Weber J; Lewis KD; Johnson D; Rivalland G; Khattak A; Majem M; Gogas H; Long GV; Currie SL; Chien D; Tagliaferri MA; Carlino MS; Diab A
Future Oncol; 2022 Mar; 18(8):903-913. PubMed ID: 35073733
[TBL] [Abstract][Full Text] [Related]
6. Treatment of a patient with HIV and metastatic melanoma with consequitive ipilimumab and nivolumab.
Tomsitz D; Hein R; Biedermann T; Kohlmeyer J
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e26-e28. PubMed ID: 28662283
[No Abstract] [Full Text] [Related]
7. 79-year Old Man on Nivolumab with Itchy Erythematous Patches.
Copur MS; Corey S
Oncology (Williston Park); 2020 Feb; 34(2):53-54. PubMed ID: 32645195
[TBL] [Abstract][Full Text] [Related]
8. Using immune checkpoint inhibitors without exacerbation in a melanoma patient with pemphigus foliaceus.
Maeda T; Yanagi T; Imafuku K; Kitamura S; Hata H; Izumi K; Ujiie H; Iwata H; Shimizu H
Int J Dermatol; 2017 Dec; 56(12):1477-1479. PubMed ID: 28762466
[No Abstract] [Full Text] [Related]
9. Predicting marker for early progression in unresectable melanoma treated with nivolumab.
Kondo T; Nomura M; Otsuka A; Nonomura Y; Kaku Y; Matsumoto S; Muto M
Int J Clin Oncol; 2019 Mar; 24(3):323-327. PubMed ID: 30168088
[TBL] [Abstract][Full Text] [Related]
10. Case of remitting seronegative symmetrical synovitis with pitting edema (RS3PE) syndrome induced by nivolumab in a patient with advanced malignant melanoma.
Wada N; Uchi H; Furue M
J Dermatol; 2017 Aug; 44(8):e196-e197. PubMed ID: 28391613
[No Abstract] [Full Text] [Related]
11. HLA-A*26 Is Correlated With Response to Nivolumab in Japanese Melanoma Patients.
Ishida Y; Otsuka A; Tanaka H; Levesque MP; Dummer R; Kabashima K
J Invest Dermatol; 2017 Nov; 137(11):2443-2444. PubMed ID: 28736235
[No Abstract] [Full Text] [Related]
12. Efficacy of nivolumab monotherapy against acral lentiginous melanoma and mucosal melanoma in Asian patients.
Maeda T; Yoshino K; Nagai K; Oaku S; Kato M; Hiura A; Hata H
Br J Dermatol; 2019 May; 180(5):1230-1231. PubMed ID: 30447078
[No Abstract] [Full Text] [Related]
13. Are checkpoint inhibitors a valuable option for metastatic or unresectable vulvar and vaginal melanomas?
Quéreux G; Wylomanski S; Bouquin R; Saint-Jean M; Peuvrel L; Knol AC; Hanf M; Dréno B
J Eur Acad Dermatol Venereol; 2018 Jan; 32(1):e39-e40. PubMed ID: 28750150
[No Abstract] [Full Text] [Related]
14. Adjuvant nivolumab shows promise in MCC.
Killock D
Nat Rev Clin Oncol; 2023 Nov; 20(11):734. PubMed ID: 37507497
[No Abstract] [Full Text] [Related]
15. Unresectable Non-metastatic Primary Melanoma: Complete Remission Following Treatment with Anti-Programmed-cell-death-receptor 1.
Lheure C; Hoffmann C; Kramkimel N; Plée J; Franck N; Vanhaecke C; Goldman-Lévy G; Bataillon G; Damotte D; Dupin N; Aractingi S; Grange F; Guégan S
Acta Derm Venereol; 2019 Jan; 99(1):107-108. PubMed ID: 30176045
[No Abstract] [Full Text] [Related]
16. Third-line pembrolizumab-induced immune-related interstitial pneumonitis after ipilimumab and nivolumab failure.
Oya K; Nakamura Y; Fujisawa Y; Endo R; Tanaka R; Ishitsuka Y; Maruyama H; Watanabe R; Okiyama N; Fujimoto M
Eur J Dermatol; 2018 Feb; 28(1):129-130. PubMed ID: 29400284
[No Abstract] [Full Text] [Related]
17. DIHS/DRESS-like eruption possibly induced by amoxicillin during treatment with nivolumab.
Takimoto R; Honda T; Kataoka TR; Ueshima C; Otsuka A; Kabashima K
Eur J Dermatol; 2019 Apr; 29(2):228-229. PubMed ID: 30973334
[No Abstract] [Full Text] [Related]
18. Late onset of nivolumab-induced severe gastroduodenitis and cholangitis in a patient with stage IV melanoma.
Cǎlugǎreanu A; Rompteaux P; Bohelay G; Goldfarb L; Barrau V; Cucherousset N; Heidelberger V; Nault JC; Ziol M; Caux F; Maubec E
Immunotherapy; 2019 Aug; 11(12):1005-1013. PubMed ID: 31304833
[TBL] [Abstract][Full Text] [Related]
19. Case of desmoplastic melanoma with lung metastasis maintaining complete response after cessation of nivolumab.
Murayama A; Itoh M; Ito K; Tanito K; Ishida K; Nobeyama Y; Nakagawa H
J Dermatol; 2017 Mar; 44(3):e17-e18. PubMed ID: 27461747
[No Abstract] [Full Text] [Related]
20. A Machine-Learning Approach to Identify a Prognostic Cytokine Signature That Is Associated With Nivolumab Clearance in Patients With Advanced Melanoma.
Wang R; Shao X; Zheng J; Saci A; Qian X; Pak I; Roy A; Bello A; Rizzo JI; Hosein F; Moss RA; Wind-Rotolo M; Feng Y
Clin Pharmacol Ther; 2020 Apr; 107(4):978-987. PubMed ID: 31721173
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
